

1 **Characterizing Potential Interaction Between Respiratory Syncytial Virus**
2 **and Seasonal Influenza in the U.S.**

3 Short Title: Potential interactions of co-circulating respiratory viral pathogens

4 Jiani Chen ^{ab}, Deven V. Gokhale ^{ac}, Liang Liu ^{bd} Pejman Rohani ^{abce}, Justin Bahl ^{abef*}

5 a. Center for Ecology of Infectious Diseases, University of Georgia, Athens, GA, 30602

6 b. Institute of Bioinformatics, University of Georgia, Athens, GA 30602

7 c. Odum School of Ecology, University of Georgia, Athens, GA 30602

8 d. Department of Statistics, University of Georgia, Athens, GA 30602

9 e. Department of Infectious Diseases, University of Georgia, Athens, GA 30602

10 f. Department of Epidemiology and Biostatistics, University of Georgia, Athens, 30602

11

12 *Email : justin.bahl@uga.edu

13

14

15 **Abstract**

16 RSV and seasonal influenza are two of the most important causes of respiratory infection that
17 consistently peak during winter months in the U.S. Here, we characterized the circulation of
18 these viruses in the U.S. with weekly positive case reports and genetic surveillance and used a
19 mathematical modeling approach to explore their potential interaction at an HHS regional level.
20 Our analyses showed RSV and seasonal influenza co-circulate with various relatively epidemic
21 sizes and seasonal overlaps across seasons and regions. We found RSV might have different
22 evolutionary dynamics compared to seasonal influenza, with local persistence may play a role in
23 underlying annual epidemics. Our analysis supports a competitive interaction between RSV and
24 seasonal influenza in most HHS regions and we speculate that cross-immunity after infection
25 might be the major driver of viral competition. Together, our work supports the competition
26 between RSV and seasonal influenza across the U.S. at a population level. Our findings are
27 important for the future development of protective strategies against these respiratory viruses.

28 **Introduction**

29 Interaction among infectious diseases has been very well documented in various polymicrobial
30 disease systems [1]. In the context of respiratory infections, a well-known example is the
31 association between the influenza virus and the bacterium pneumococcus, driven by enhanced
32 susceptibility to secondary bacterial colonization subsequent to influenza infection [2][3][4].
33 Another important example comes from the 2009 influenza A pandemic (H1N1pdm09), with
34 data from several European countries indicating that the spread of the virus might have been
35 interrupted by the annual autumn rhinovirus epidemic [5]. These pathogen-pathogen interactions
36 may lead to cooperation or competition, and their co-occurrence within the same host population

37 can profoundly alter the pathogenesis and spread of infectious diseases with substantial public
38 health consequences [6].
39
40 Respiratory Syncytial Virus (RSV) and seasonal influenza virus (Flu) are two of the most
41 important causes of respiratory infection [7][8][9]. Both RSV and seasonal influenza activity
42 consistently peak during winter months in the US. However, the relative disease burden and
43 similarity between the epidemic timing of these viruses vary substantially among regions and
44 seasons [9], [10]. The burden of influenza varies from season to season, depending in part on the
45 dominant virus type or subtypes in circulation [11]. Influenza subtypes A/H3N2 and A/H1N1
46 (Flu A) have become the leading cause of seasonal influenza illness and death in the U.S. over
47 the last 50 years [12]. Additionally, two distinct lineages of the influenza B (Flu B) virus,
48 Victoria and Yamagata, co-circulate or alternate with Flu A and have received greater attention
49 in recent years [13]. Intensive studies of the molecular evolution of the influenza virus have
50 provided important insights into its seasonal emergence and spread in human populations
51 [11][14][12][13]. Similar to seasonal influenza, two distinct antigenic subgroups of RSV have
52 been identified, RSV-A and RSV-B, which show clear phylogenetic divergence. Genotype ON
53 (RSV-A) and BA (RSV-B) are the two most prevalent RSV genotypes that are circulating in the
54 U.S. in recent years [15][16], [17]. However, the molecular epidemiology of RSV is largely
55 unknown both on local and global scales [18]. Since RSV and seasonal influenza have similar
56 seasonality and clinical presentation, researchers often try to extrapolate knowledge gleaned
57 from the study of seasonal influenza to RSV to understand viral dynamics and develop protective
58 strategies against these respiratory viruses-induced illnesses together [19]. Therefore, elucidating
59 the exact nature of the interaction between RSV and seasonal influenza can greatly enhance our

60 ability to forecast future epidemics, and substantially inform the development and
61 implementation of control strategies.

62
63 Both biological and epidemiological studies suggest potential competitive interaction between
64 RSV and seasonal influenza [20]. The proposed biological mechanism for the competition
65 between these viruses is the activation of the innate “antiviral response” by an infection that can
66 inhibit further or subsequent infection of another virus, resulting in a period of cross-protection
67 during or after infection [18], [21]. Epidemiological data show that when rates of infection with
68 RSV are high, influenza infections are low; the converse is also true [22]. The interaction
69 between respiratory viruses has the potential to impact virus genetic diversity and epidemics
70 pattern and therefore would lead to the observed patterns in phylogenetics or surveillance data
71 [11], [25]. Previous studies have demonstrated the application of dynamic modeling to test
72 biological hypotheses on pathogen interaction mechanisms and it could be used to infer the
73 interaction between RSV and seasonal influenza [23]. However, very few studies examine the
74 potential interaction between RSV and seasonal influenza on a population level, and the explicit
75 mechanism of their interaction has not been well-studied.

76
77 In this study, we initially carry out a phylogenetic analysis to elucidate differences in the
78 evolutionary trajectories of RSV and seasonal influenza. We then apply a seasonally forced, two-
79 pathogen, mechanistic transmission model to explicitly investigate the nature of ecological
80 interference between RSV and seasonal influenza and quantify its effects in driving transmission
81 dynamics in different regions in the U.S. Our analysis provides evidence of the potential negative

82 interaction of RSV and seasonal influenza on the ecological scale and the cross-immunity after
83 infection might be an important mechanism.


84

85 **Results**

86

87 **Seasonality overlaps between RSV and seasonal influenza**

88 Different relative epidemic sizes and peaking times of RSV and seasonal influenza can be
89 observed across different HHS regions in the U.S. (SI Appendix, Fig. S1, represented regions are
90 shown in Fig.1A). We computed the correlation coefficient of these viruses using weekly
91 surveillance reports and found the positive case of RSV and seasonal influenza increased with
92 another (Fig.1B, SI Appendix, Table S1), suggesting epidemic seasonality similarities between
93 these viruses in the U.S. In addition, the magnitude of the correlation between RSV and seasonal
94 influenza are various across HHS regions, with a relatively high value in HHS Regions 6, 7, and
95 10 between RSV and Flu A and in HHS regions 6, 7, and 8 between RSV and Flu B. We further
96 computed the time-lagged correlation of different pairs of viruses (Fig.1C) to measure the
97 temporal association between RSV and seasonal influenza epidemics in the U.S. In our analysis,
98 we observed the maximize correlation with zero to little (positive/negative) time lags in different
99 regions, indicating the seasonality overlap between RSV and seasonal influenza are different
100 across regions and might have different interaction patterns.




101
 102 **Fig. 1. Correlation coefficient of RSV and seasonal influenza epidemics in the U.S. A.**
 103 Weekly RSV and seasonal influenza epidemics in represented HHS regions (HHS Region

104 4,7,8,10). **B.** Correlation coefficient between RSV and seasonal influenza weekly surveillance
105 reports (Table S1). Relative color in HHS regions indicates the normalized correlation
106 coefficient of weekly positive samples of the different pairs of viruses. **C.** Time-lagged
107 correlation coefficient between RSV and seasonal influenza (Table S2). The time lags (week)
108 that maximize the correlation coefficient in each HHS region are labeled with *. Negative values
109 indicate a leading correlation and positive values indicate a lagging correlation. Lighter-colored
110 indicate a higher correlation coefficient between two viruses and darker-colored indicate a lower
111 correlation coefficient.

112 **Population dynamics of RSV and seasonal influenza**

113 We characterized the population dynamics of RSV and seasonal influenza using a phylogenetic
114 approach. The phylogenies of seasonal influenza lineages were estimated using Hemagglutinin
115 (HA) gene segments that were collected in the U.S. during the 2011-2019 seasons. The analyses
116 of RSV were based on G gene sequences from northern hemisphere countries in the same period
117 and we focus on genotypes ON and BA. We calculated the time-sliced statistics (Materials and
118 Methods, TMRCA: Time to the most recent ancestor, and Diversity: branch distance between
119 pairs of tips) from RSV and seasonal influenza phylogenies (Fig. 2A). A periodic reduction in
120 TMRCA and diversity across time can be observed from seasonal influenza phylogenies (H1,
121 H3, Victoria, and Yamagata). In contrast, TMRCA and diversity scores of RSV phylogenies
122 increased across time, except for the analysis of BA in recent seasons, which might be due to a
123 lack of RSV sampling during recent sampling times. In addition, Bayesian "Skyride" coalescent
124 reconstructions demonstrate strong periodicity of seasonal influenza viruses, which are
125 correlated with their seasonal epidemic patterns, though we observed very low genetic diversity
126 of Flu B lineages in some years. The population dynamics of RSV did not show seasonal

127 fluctuation and both ON and BA genotypes presented peaks from 2011 to 2019 (Fig.2B, Fig.2C).
 128 These different phylogenetic patterns suggest local persistence may play a role in underlying
 129 annual epidemics of RSV and influenza strains are under constant negative selection.
 130



131
 132 **Fig. 2. Population dynamics of RSV and seasonal influenza in the U.S. A.** Phylogenies and
 133 corresponding time-slice statistics. The time-slice TMRCA and Diversity are calculated by
 134 breaking the phylogeny into multiple temporal sections. TMRCA, time to the most common
 135 ancestor of all tips within temporal sections. Diversity is the average time to coalescent for pairs
 136 of lineages within temporal sections. TMRCA and Diversity are measured in the unit of years.
 137 Solid lines represent mean values and gray outlines represent 95% CI across MCMC replicates.


138 **B. Surveillance curve and reconstructed effective population size of RSV and seasonal influenza**
139 using GMRF Bayesian “Skyride” analysis. Solid lines represent mean values and outlines
140 represent 95% CI across MCMC replicates.

141
142 We computed the correlation coefficient using these estimated time series effective population
143 sizes of RSV and seasonal influenza to explore their potential association at the virus population
144 level (SI Appendix, Table S2). Significant negative correlation coefficients can be observed
145 between RSV and seasonal influenza strains: RSV-A genotype ON with influenza H3 (CI: -
146 0.513, -0.128), H1 (CI: -0.482, -0.087), and Victoria (CI: - 0.482, -0.087); RSV-B genotype BA
147 with influenza H1 (CI: -0.506, -0.138) and Yamagata (CI: -0.564, -0.217), which indicate these
148 viruses might have a negative association.

149
150 **Potential competition between RSV and seasonal influenza**

151 The co-circulation of RSV and seasonal influenza suggests a transmission model that allows the
152 co-infection of these viruses is required. Therefore, we adapted a two-pathogen transmission
153 model to investigate the potential competition between RSV and seasonal influenza (SI
154 Appendix Fig.S4, Table S3, Table S4) in the U.S. This model accommodates two mechanisms of
155 competition between pathogens. Competition may arise through the inhibition of co-infection,
156 which is modeled by scaling the transmission rates of secondary infections with parameter ψ . In
157 addition, following infection with one pathogen, individuals may gain short-term cross-immunity
158 against another pathogen and can be similarly modeled by scaling the force of secondary
159 infection by χ . Changing the value of these two parameters can influence the timing, magnitude,
160 and shape of observed epidemics (Fig. 3).

161



162

163 **Fig. 3. Simulation study to examine the effects of the proportion of inhibition of co-infection**

164 **(ψ) and cross-immunity after infection (χ) using a two-pathogen transmission model. A.**

165 Changes in relative peak case ratio and the relative time of peaks based on the values ψ and χ in

166 the model. B. Simulated trajectories resulting from parameter values of ψ and χ selected at

167 points a, b, c, and d in A.

168

169 We fit this model to RSV and type-specific seasonal influenza (Flu A or Flu B) incidence data

170 that are collected from 10 HHS Regions from 2014 to 2017 and use Akaike Information

171 Criterion (AIC) values to compare four different hypotheses regarding the interaction between

172 RSV and seasonal influenza: (1) no interaction ($\chi = \psi = 1$); (2) inhibition of co-infection ($\psi <$

173 1, $\chi = 1$); (3) transient cross-immunity after infection ($\psi = 1, \chi < 1$); and (4) both the
174 inhibition of co-infection and transient cross-immunity ($\psi < 1, \chi < 1$)(SI Appendix Table S5).
175 In these analyses, the duration of short-lived cross-protection is fixed at 6 months [24]. We
176 estimated parameters that could optimize the likelihood estimates of the model under each
177 hypothesis in 10 HHS regions (SI Appendix Table S7 to Table S16). The virus-specific
178 simulated trajectories under four hypotheses for 10 HHS regions are shown in SI Appendix, Fig.
179 S5. We found that adding competitive interaction between RSV and seasonal influenza provides
180 a better explanation of the surveillance data in most regions except for HHS Region 8 (SI
181 Appendix, Table S6), and the epidemic trajectories from surveillance data in different HHS
182 regions can be well fit under the corresponding best hypothesis as examined by Root Mean
183 Square Error (RMSE) (SI Appendix, Fig. S6). As described in Table 1, different levels of cross-
184 immunity after infection were estimated across HHS regions under the corresponding best
185 hypothesis, and the inhibition of co-infections was also supported in some regions (HHS Regions
186 1, 3, 4, 5, 6, 7 for RSV and Flu A, HHS Regions 3, 5, 6, 10 for RSV and Flu B). We used HHS
187 Region 1 as an example region to demonstrate our findings: our analysis suggests RSV and Flu
188 A are fully inhibited to be co-infected and there was also a short-term cross-immunity, with a
189 45% reduction in the infection rate of another pathogen. By fitting the RSV and Flu B
190 surveillance, we found a 39% reduction in the infection of the second virus, and the inhibition of
191 co-infection was not supported (Fig. 4, Table 2).


192

193 **Table 1. Competition parameter estimates under the best fit hypothesis for seasons 2014-**
 194 **2018 in 10 HHS regions.**

195

HHS region	RSV-Flu A		RSV-Flu B	
	Inhibition of co-infection(ψ)	Cross-immunity after infection(χ)	Inhibition of co-infection(ψ)	Cross-immunity after infection(χ)
1	0	0.55	1	0.64
2	1	0.69	1	0.72
3	0	0.59	0	0.8
4	0.57	0.37	0	0.87
5	0	0.78	1	0.61
6	0	0.77	1	0.45
7	0	0.52	0.95	0.64
8	1	1	1	1
9	1	0.79	0.2	0.6
10	1	0.5	1	0.2

196



197 **Fig. 4. Relative fits of four epidemiological hypotheses for season 2014-2017 in HHS Region**
 198 **1. Matched virus-specific simulated trajectories under four hypotheses are shown in different**

199 **colors (Mean in solid line and 95% CI in shading). The black solid line represented the HHS**
 200 **observed trajectories.**

201 regional level weekly case report data. **A.** The test of the interaction between RSV and Flu A. **B.**

202 The test of the interaction between RSV and Flu B.

203 **Table 2. Parameters estimates and epidemiological hypotheses evaluation for season 2014-**
 204 **2017 in HHS regions 1**


205

Parameter	No interaction	Inhibition of co-infection	Cross-immunity after infection	Inhibition of co-infection and cross-immunity after infection
RSV-Flu A				
R_0^{RSV}	1.49	1.46	1.84	1.89
R_0^{Flu}	1.37	1.05	1.31	1.27
b_{RSV}	0.26	0.33	0.13	0.15
b_{Flu}	0.1	0.27	0.17	0.23
t_0^{RSV}	0.91	0.93	0.98	0.99
t_0^{Flu}	0.1	0.03	0.12	0.11
ψ	1	0	1	0
χ	1	1	0.47	0.55
δ_{RSV}	2.49E-04	2.45E-04	2.07E-04	1.97E-04
δ_{Flu}	6.49E-04	1.07E-03	8.94E-04	9.34E-04
loglik	-4946.37	-3966.74	-3673.11	-3463.34
AIC	9908.74	7951.49	7364.22	6946.68
ΔAIC	2962.06	1004.81	417.54	0
RMSE	62.47	52.51	50.36	49.3
RSV-Flu B				
R_0^{RSV}	1.49	1.49	1.34	1.36
R_0^{Flu}	1	1	1	1.09
b_{RSV}	0.26	0.26	0.29	0.3
b_{Flu}	0.28	0.32	0.38	0.32
t_0^{RSV}	0.91	0.92	0.9	0.9
t_0^{Flu}	0.14	0.14	0.16	0.16
ψ	1	0	1	0.02
χ	1	1	0.64	0.61
δ_{RSV}	2.49E-04	2.49E-04	3.33E-04	3.17E-04
δ_{Flu}	2.69E-04	2.69E-04	2.74E-04	2.47E-04
loglik	-1504.85	-1491.16	-1353.99	-1376.56
AIC	3025.7	3000.32	2725.99	2773.13
ΔAIC	299.71	274.33	0	47.14
RMSE	11.14	11.28	11.03	12.06

206
 207 R_0^i , reproductive number of pathogen i , b_i , the amplitude of seasonality of pathogen i , t_0^i , the
 208 timing of seasonal peak for pathogen i . δ_i , the case report rate for pathogen i . The goodness of fit
 209 under different hypotheses was assessed using the Akaike information criterion (AIC), ΔAIC is
 210 calculated by the difference with the lowest AIC value using the same dataset. RMSE is used to
 211 quantify how well the model fits with surveillance data.

212
 213

214 We further estimated the credible interval (CI) of the two competitive parameters under the best-
215 fit hypothesis in 10 HHS regions (SI Appendix, Fig. S7). As shown in the analysis of HHS
216 Region 1 (Fig. 5), changing the values of ψ have relatively small effects on the likelihood profile
217 compared with the strength of cross-protection (χ), and the CI of χ can be well identified (RSV
218 and Flu A: 0.522, 0.567, RSV and Flu B: 0.628, 0.638). Our results indicate that short-term
219 cross-immunity after the infection might be the major mechanism to explain the competition
220 between RSV and seasonal influenza.



221
222 **Fig. 5. Likelihood profile tests of competition interaction parameters for RSV and seasonal**
223 **influenza, inferred in HHS Region 1 from 2014 to 2017.** Plotted in each graph is the likelihood
224 profile for the inhibition of co-inhibition (ψ) in green and the cross-immunity after infection (χ)
225 in orange, which are lines connected by repeated likelihood estimates ($N = 20$, shown in colored
226 solid circles). The values within the two dashed lines are within the estimated 95% CI. **A.** The

227 test of the interaction between RSV and Flu A. **B.** The test of the interaction between RSV and
228 Flu B.

229

230 **Discussion**

231 In this study, we demonstrate the circulation dynamics of RSV and seasonal influenza in the U.S
232 and examine their potential competition and mechanism at a population level. Our phylogenetic
233 analyses initially suggest there might be a negative association between RSV and seasonal
234 influenza by studying the correlation of their estimated time-series genetic diversity. We further
235 study this potential negative interaction explicitly by applying a two-pathogen transmission
236 model with HHS regional-level surveillance reports. Taken together, our analyses provide
237 statistical support for the negative interaction between RSV and seasonal influenza after
238 infection.

239

240 By studying the co-circulation of RSV and seasonal influenza in different regions of the U.S, we
241 confirm the temporal correlation between these viruses. We found there might be little to zero
242 number of weeks of time-lags to maximize the correlation coefficient between RSV and different
243 subtypes of influenza. These differences in relative epidemic peaks of RSV and seasonal
244 influenza across different HHS regions in the U.S suggests they might interact with different
245 severity.

246

247 Phylogenetic analysis can be used to estimate the virus's genetic diversity through time and
248 therefore has the potential to reflect the effects of interactions between viruses. Previous
249 phylogenetic studies of seasonal influenza demonstrated a periodicity in the relative genetic

250 diversity in temperate zones where regional epidemics have coinciding epidemic peaks and
251 seasonal patterns [27]. A similar seasonality of RSV was also reported in multiple Northern
252 Hemisphere countries experiencing a temperate climate, with the annual epidemics starting in the
253 autumn, peaking in winter, and ending in spring [28]–[30]. Therefore, we expect a similar
254 seasonal periodicity in relative genetic diversity could be observed in the RSV phylogenetic
255 analyses with sequences that are collected from available northern hemisphere countries.
256 However, our phylogenetic analyses of RSV suggest a different pattern of seasonal influenza and
257 indicate the potential of regional persistence, which is consistent with previous phylogenetic
258 studies of RSV in other regions [31]–[32], [33]. The antigenic drift of seasonal influenza creates
259 competition among strains, resulting in the emergence of selective forces and previously
260 circulating strains can be prone to local extinction each year [34]. This negative selection
261 including the effect of the vaccine causes rapid influenza population turnover and therefore it
262 only takes a few years for contemporaneous strains to find a common ancestor [35], [36]. In
263 contrast, RSV phylogenies harbor many deep branches in our analysis (Fig. 2). This
264 reconstructed population dynamics of RSV might indicate latency supported by low levels of
265 circulation during the summer season that is not captured by current RSV genomic surveillance
266 [33], and RSV seasonal epidemics could be driven by other ecological factors like humidity,
267 temperature, and human contact or travel [28][37]. These differences between RSV
268 and influenza suggest in phylogenies suggest different protection and vaccine strategies may be
269 needed against these viruses [34][35], [36]. We observe a negative correlation between RSV and
270 seasonal influenza lineages with time series effective population sizes that are estimated from
271 genetic data, which suggests a potentially negative interaction between these viruses on an
272 ecological scale. However, our analyses are limited by the lack of genetic surveillance effort and

273 more explicit analyses are still needed to study the potential competition between RSV and
274 seasonal influenza.

275

276 Our transmission modeling work provides additional evidence of the negative interaction
277 between RSV across regions and seasonal influenza and further demonstrates the potential
278 mechanism of interaction. We find adding inhibition on co-infection to the model has relatively
279 small effects on epidemic trajectories from a simulation study (Fig.3), and the inhibition on co-
280 infection is not supported by the surveillance data from some HHS regions. This might be due to
281 the short infection period of RSV and seasonal influenza, and only a small proportion of the
282 population has the potential to be infected by two viruses simultaneously and therefore do not
283 leave a strong dynamical footprint in population-level weekly surveillance data. In our analyses,
284 there are very few individuals to be infected by RSV and seasonal influenza simultaneously,
285 which is consistent with previous surveillance studies that suggest the observed incidence of co-
286 infectivity of RSV and influenza was significantly less than expected [9]. To further confirm our
287 estimation, the exact number of cases with co-infection is needed. In addition, the severities of
288 competition between these viruses across HHS regions are estimated to be different from our
289 analysis. The population structure (e.g. age) in different regions might cause different levels of
290 cross-pathogen immunity [18]. It is also important to note that the surveillance reporting
291 institutions vary across regions, which may result in different levels of competition that are
292 reflected in the surveillance data. These location-specific features need to be considered when
293 generalizing the findings.

294

295 Much of the previous evidence for the interaction between RSV and seasonal influenza is on an
296 individual, biological level [38][25][24][39][21]. Previous evidence of the interaction of RSV
297 and seasonal influenza on the population level implies that prevention of one could inadvertently
298 lead to an increase in the burden of the other [23][26]. Recent modeling work suggests a
299 competition between RSV and influenza with infection reducing heterologous acquisition by
300 41% for 10 days among children after infection in Nha Trang, Vietnam [40]. We provide
301 additional evidence for the competition between RSV and influenza at the population level in a
302 more diverse region in the U.S. and the level of competition could be differentiated by location.
303 While our findings are consistent with previous experimental studies and modeling work
304 suggests a competitive interaction between RSV and influenza [20][21][41][42], it is important
305 to emphasize social behavioral changes after infection (sequestration during convalescence) with
306 a virus may also play a role [43].

307
308 To simplify the analyses with the transmission model, we assume RSV-influenza interaction is
309 bidirectional and the strength and duration of interaction that influenza exhibits on RSV are the
310 same and vice versa. We do not model RSV and two subtypes of seasonal influenza together
311 because adding another virus would significantly increase the complexity of the model and we
312 believe there is a low chance for individuals to be infected with RSV and two subtypes of
313 seasonal influenza within a short time. To reduce the number of parameters that need to be
314 estimated, we fix the cross-protection period with a relatively long time of 6 months [44] and we
315 assume the cross-immunity could protect the individual to be less likely infected by another
316 pathogen at the same season. Our analysis is also limited by current RSV and seasonal influenza
317 surveillance availability. We are lacking RSV subtype information in the current surveillance

318 support. In addition, the reporting institutions of RSV and seasonal influenza surveillance vary
319 between years, and spikes in detections may reflect increased testing within a given surveillance
320 year. Hence, additional high-quality surveillance data in the future might be able to draw a more
321 reliable conclusion.

322
323 Overall, we characterize the seasonal overlaps and evolutionary dynamics of RSV and seasonal
324 influenza and focus on their potential interaction. Our work highlights the use of mathematical
325 mechanistic models to test the interaction hypothesis of RSV and seasonal influenza. Although
326 more effort is needed, our results suggest a cross-immunity-induced negative interaction of RSV
327 and influenza on the ecological scale and can be identified in surveillance data. This study is
328 helpful to have a better understanding of the different dynamics and the potential interaction
329 between RSV and seasonal influenza, which are critical for predicting the effects of alteration of
330 their ecological balance and designing vaccines against these viruses.

331

332 **Materials and Methods**

333

334 **RSV and seasonal influenza surveillance data**

335 PCR reports from HHS regional-level surveillance data for RSV that are collected from 2011 to
336 2019 were requested from CDC's National Respiratory and Enteric Virus Surveillance System
337 (NREVSS). HHS regional-level type-specific seasonal influenza (Flu A / Flu B) positive test
338 reports were downloaded from FluView Interactive [45], and the viral surveillance reported by
339 Clinical Labs was used after the year 2015. The national-level surveillance data were aggregated
340 from the reports of 10 HHS regions.

341

342 **Correlation coefficient estimation**

343 To measure the association between RSV and seasonal influenza epidemic, we computed
344 correlation coefficients with weekly surveillance reports of different pairs of viruses in each
345 HHS region in R v4.1. The weekly positive cases / million individuals of each virus were
346 calculated by the estimated population for each HHS region in the given year, which were
347 collected from the U.S. Census Bureau using the “State Population Totals and Components of
348 Change: 2010-2019” data set [46]. We employed the Shapiro-Wilk normality test to test for the
349 normality of the error distribution of the time series being compared. Pearson’s correlation
350 coefficient was used to quantify the linear association among the co-circulating viral dynamics
351 and the association was taken to be statistically significant at a p-value < 0.05 in a t-test. The
352 time-lagged correlation coefficient was estimated in R package `astsa` v1.15 [47].

353

354 To examine the correlation of the genetic diversity for RSV and seasonal influenza, `approx()`
355 interpolating function in R was used to generate the effective population sizes of different virus
356 strains at the same time points from 2011-2019 from their corresponding Bayesian “Skyride”
357 analysis. After examining the normality of the data using Shapiro-Wilk normality test, we used
358 Pearson’s correlation coefficient test to measure the correlation of RSV and seasonal influenza

359

360 **Genetic datasets**

361 HA segments of seasonal influenza (H3, H1, Victoria, and Yamagata) were retrieved from the
362 GISAID database spanning the 2011-2019 epidemic seasons (generally considered as the
363 October of the start year through May of the following year) in the U.S. Due to the lack of

364 sampling for RSV in the US and North America regions, RSV G gene sequences (at least 70%
365 length of complete G gene) that are collected from available northern hemisphere countries
366 during the same period were retrieved from the GISAID database. RSV genotypes were
367 determined with a reference dataset using NCBI BLAST [48], [49] and further confirmed with
368 phylogenetic analyses, and sequences belonging to the dominant genotypes “ON” (RSV-A) and
369 “BA” (RSV-B) were selected for the following analysis.

370
371 Nucleotide sequences that belong to each genotype were aligned using MAFFT.v7 [50]
372 separately and initial maximum likelihood (ML) phylogenetic trees were built using RAxML.v8
373 [51]. The temporal signal of each dataset was analyzed using TempEst v1.5.3 [52] and temporal
374 outliers were removed for further studies. These ML phylogenies for seasonal influenza in
375 different subtypes were further used to subsample to a maximum of 100 isolates in each season
376 using the Phylogenetic Diversity Analyzer (PDA) [53]. These subsampled datasets were used for
377 the subsequent Bayesian phylogenetic analyses. The final datasets contained 1004 ON1, 769 BA
378 RSV G gene sequences, 867 H3, 871 H1, 796 Victoria, and 789 Yamagata HA gene segments of
379 seasonal influenza.

380

381 **Bayesian phylogenetic analysis**

382 Evolutionary dynamics of RSV and seasonal influenza were estimated with a Bayesian
383 phylogenetic approach using BEAST v.1.10.4[54]. A generalized time-reversible nucleotide
384 substitution model with gamma rate heterogeneity was used for the analysis of RSV and the
385 SRD06 codon position model was used for the analysis of seasonal influenza [55][56].

386 Uncorrelated lognormal relaxed clock and GMRF Skyride coalescent model [57] were used to

387 estimate the population dynamics of the virus during each season for both pathogens. At least 4
388 independent MCMC chains of 150-200 million generations were simulated to ensure a sufficient
389 effective sample size ($ESS > 200$) as diagnosed in Tracer v1.7 [58]. LogCombiner v1.10.4 was
390 used to combine the multiple runs and the Maximum Clade Credibility (MCC) tree was
391 summarized in TreeAnnotator v1.10.4 after the removal of the 10% burn-in. Temporal-sliced
392 descriptive statistics, including TMRCA estimates, diversity measurements, and mean statistics
393 including coalescent rate, diversity, and Tajima's D scores were calculated from BEAST
394 sampled Bayesian phylogenetic trees using the software package PACT v0.9.3 [35].

395

396 **Two pathogen transmission model**

397 We applied a two-pathogen transmission model to study the potential interaction of RSV and
398 seasonal influenza [59]. The population is compartmentalized into Susceptible (S), Infectious (I),
399 Cross-protected (C), and Recovered (R) for each pathogen i , ($i \in 1,2$)[59], [60]. Transitions
400 among these compartments were governed by the following processes. Susceptible individuals
401 with no immunity are infected at rates λ_i and enter the corresponding I compartment. Following
402 the infectious period (with a mean duration of $1/\gamma_i$), individuals recover and move to the C
403 compartment, where individuals are fully protected against homologous re-infection and have
404 some cross-immunity against another virus. Individuals then lose this cross-immunity but retain
405 pathogen-specific immunity in moving to the R compartment at rate ρ . Pathogen-specific
406 immunity wanes as individuals become susceptible again at rate ω . The birth-death rate at each
407 compartment is μ .

408

409 We hypothesize that the infection with another pathogen might be less likely either during or
410 after the infection of the first pathogen, corresponding to either the I or C compartments, and
411 therefore we define the infection rate of another pathogen with the potential of reduction. In the I
412 compartment, an interaction corresponds to a reduction in the infection rate of the second
413 pathogen at $\psi\lambda_i$, where the inhibition to be co-infected is modeled by scaling the rates of
414 infection using a value between 0 and 1 ($\psi \in [0,1]$). In the C compartment, we similarly model a
415 reduced infection rate $\chi\lambda_i$ for the second virus, wherein the strength of cross-immunity, χ , takes
416 a value between 0 and 1 ($\chi \in [0,1]$). Parameters and estimated values used in the model are
417 shown in SI Appendix, Table S4. In a deterministic setting, the model is described by 16
418 ordinary differential equations (Table S3, Equations for each state can be read directly from SI
419 Appendix, Fig. S3).

420
421 The inhibition of co-infection was modeled by a reduction in the infection rate to the second
422 virus, $\psi\lambda_i$ ($\psi \in [0,1]$), the equations governing these dynamics are given by:

$$423 \quad \frac{dX_{SI}}{dt} = \omega_1 X_{RI} + \lambda_2 X_{SS} - \gamma_2 X_{SI} - \psi\lambda_1 X_{SI} - \mu X_{SI} \quad 1$$

$$424 \quad \frac{dX_{IS}}{dt} = \lambda_1 X_{SS} + \omega_2 X_{IR} - \gamma_1 X_{IS} - \psi\lambda_2 X_{IS} - \mu X_{IS} \quad 2$$

$$425 \quad \frac{dX_{II}}{dt} = \psi\lambda_1 X_{SI} + \psi\lambda_2 X_{IS} - \gamma_1 X_{II} - \gamma_2 X_{II} - \mu X_{II}. \quad 3$$

426
427 The cross-immunity after the infection was modeled by a reduced infection rate to the second
428 virus $\chi\lambda_i$ ($\chi \in [0,1]$) at the C compartment:

$$429 \quad \frac{dX_{IC}}{dt} = \chi\lambda_1 X_{SC} + \gamma_2 X_{II} - \gamma_1 X_{IC} - \rho_2 X_{IC} - \mu X_{IC} \quad 4$$

430
$$\frac{dX_{CI}}{dt} = \gamma_1 X_{II} + \chi \lambda_2 X_{CS} - \rho_1 X_{CI} - \gamma_2 X_{CI} - \mu X_{CI}. \quad 5$$

431 The overall population in this model is the sum of the populations in each compartment:

432

433
$$N = X_{SS} + X_{SI} + X_{SC} + X_{SR} + X_{IS} + X_{II} + X_{IC} + X_{IR} + X_{CS} + X_{CI} + X_{CC} + X_{CR} + X_{RS} + X_{RI} + X_{RC} + X_{RR}. \quad 6$$

434

435 For virus i ($i \in \{1,2\}$) in this model, seasonality in the transmission rate ($\beta_i(t)$) was
 436 incorporated in the transmission model, where R_0^i is the basic reproductive number, b_i is the
 437 amplitude of seasonality, and t_0^i is the peak transmission day during the season:

438
$$\beta_i(t) = \gamma_i R_0^i \left[1 + b_i \cos \left(2\pi \frac{t - t_0^i}{T} \right) \right]. \quad 7$$

439 The force of infection depends on the number of individuals infected with the virus i and the rate
 440 at which cases are imported into the population from external sources η_i .

441
$$\lambda_1(t) = \beta_1(t) \frac{X_{IS} + X_{II} + X_{IC} + X_{IR} + \eta_1}{N} \quad 8$$

$$\lambda_2(t) = \beta_2(t) \frac{X_{SI} + X_{II} + X_{CI} + X_{RI} + \eta_2}{N}. \quad 9$$

442 The deterministic model was implemented in R using the package “pomp” [61]. For the
 443 likelihood-based inference, we generated the observed cumulative number of cases (K_i)
 444 according to the following equations, where δ_i is the case report rate of the virus.

445
$$\frac{dK_1}{dt} = \delta_1 (\gamma_1 X_{IS} + \gamma_1 X_{II} + \gamma_1 X_{IC} + \gamma_1 X_{IR}) \quad 10$$

$$\frac{dK_2}{dt} = \delta_2 (\gamma_2 X_{SI} + \gamma_2 X_{II} + \gamma_2 X_{CI} + \gamma_2 X_{RI}). \quad 11$$

446

447 We initiated the model with an endemic equilibrium of the non-interacting model ($\psi = 1, \chi = 1$)
448 without seasonality ($b_1 = 0, b_2 = 0$), the first 100 years were discarded as transient dynamics
449 before the likelihood calculation.

450

451 **Hypothesis testing and parameter estimation**

452

453 The model was fit with RSV and type-specific seasonal incidence surveillance that are collected
454 in 10 HHS regions from 2014 to 2017. Maximum-likelihood estimates (MLEs) for the unknown
455 parameters were found using trajectory matching. Differential evolution algorithm (DEoptim) for
456 global optimization implemented in R package “DEoptim” [62] was used to find the estimates
457 that maximize the MLE. We calculated AIC using MLE estimates under each hypothesis. If a
458 model is more than 2 AIC units lower than another, we then consider it significantly better.
459 RMSE was calculated to quantify how well the model fits with surveillance data. As proof of
460 concept, we performed an out-of-sample simulation to demonstrate the suitability of the MLE
461 model; that is, we generated the forecast for the following season of the MLE model with the
462 estimated parameters and then compare the simulated cases with RSV and seasonal influenza
463 surveillance that are collected in each HHS region.

464

465 We performed a simulation study to estimate the uncertainty of the competitive interaction
466 parameters. We created likelihood profiles for the respective parameters by fitting a smooth line
467 through the log of repeated likelihood estimates in which the respective parameter is a fixed
468 value. The 95% CI is taken to $\chi_1^2(0.95)/2 \approx 1.92$ log-likelihood units below the maximum
469 likelihood estimates using the χ^2 distribution.

470

471 **Data availability**

472

473 Source code and data have been deposited on GitHub: https://github.com/JianiC/RSV_flu

474 The GISAID accession number of RSV and seasonal influenza sequence of this study are
475 available in supplementary materials.

476

477 **Acknowledgments**

478

479 We acknowledge the RSV surveillance data from the NREVSS team and subtype-specific
480 seasonal influenza surveillance data from the CDC's FluView Interactive. We acknowledge the
481 originating and submitting laboratories for our use of sequences from the GISAID's EpiFlu and
482 EpiRSV Database.

483

484 **References**

485

486 [1] B. M. Peters, M. A. Jabra-Rizk, G. A. O'May, J. W. Costerton, and M. E. Shirtliff,
487 "Polymicrobial interactions: impact on pathogenesis and human disease," *Clin. Microbiol.*
488 *Rev.*, vol. 25, no. 1, pp. 193–213, Jan. 2012, doi: 10.1128/CMR.00013-11.

489 [2] S. Shrestha, B. Foxman, D. M. Weinberger, C. Steiner, C. Viboud, and P. Rohani,
490 "Identifying the interaction between influenza and pneumococcal pneumonia using
491 incidence data.," *Sci. Transl. Med.*, vol. 5, no. 191, p. 191ra84, Jun. 2013, doi:
492 10.1126/scitranslmed.3005982.

- 493 [3] M. Lipsitch *et al.*, “Estimating Rates of Carriage Acquisition and Clearance and
494 Competitive Ability for Pneumococcal Serotypes in Kenya With a Markov Transition
495 Model,” *Epidemiology*, vol. 23, no. 4, 2012, [Online]. Available:
496 [https://journals.lww.com/epidem/Fulltext/2012/07000/Estimating_Rates_of_Carriage_Ac-](https://journals.lww.com/epidem/Fulltext/2012/07000/Estimating_Rates_of_Carriage_Acquisition_and.2.aspx)
497 [quisition_and.2.aspx](https://journals.lww.com/epidem/Fulltext/2012/07000/Estimating_Rates_of_Carriage_Acquisition_and.2.aspx).
- 498 [4] L. Opatowski *et al.*, “Assessing pneumococcal meningitis association with viral
499 respiratory infections and antibiotics: insights from statistical and mathematical models,”
500 *Proc. R. Soc. B Biol. Sci.*, vol. 280, no. 1764, p. 20130519, Aug. 2013, doi:
501 [10.1098/rspb.2013.0519](https://doi.org/10.1098/rspb.2013.0519).
- 502 [5] A. Wu, V. T. Mihaylova, M. L. Landry, and E. F. Foxman, “Interference between
503 rhinovirus and influenza A virus: a clinical data analysis and experimental infection
504 study,” *The Lancet Microbe*, vol. 1, no. 6, pp. e254–e262, 2020, doi:
505 [https://doi.org/10.1016/S2666-5247\(20\)30114-2](https://doi.org/10.1016/S2666-5247(20)30114-2).
- 506 [6] F. Pinotti, F. Ghanbarnejad, P. Hövel, and C. Poletto, “Interplay between competitive and
507 cooperative interactions in a three-player pathogen system,” *R. Soc. Open Sci.*, vol. 7, no.
508 1, p. 190305, Mar. 2022, doi: [10.1098/rsos.190305](https://doi.org/10.1098/rsos.190305).
- 509 [7] M. Tin Tin Htar, M. S. Yerramalla, J. C. Moïsi, and D. L. Swerdlow, “The burden of
510 respiratory syncytial virus in adults: a systematic review and meta-analysis,” *Epidemiol.*
511 *Infect.*, vol. 148, pp. e48–e48, Feb. 2020, doi: [10.1017/S0950268820000400](https://doi.org/10.1017/S0950268820000400).
- 512 [8] J. Nunes Caldeira Marinho Matos, S. Rodrigues Sousa, M. Braz, Y. Martins, and F.
513 Barata, “Characterization of influenza A, B and RSV infections in a Pulmonology ward
514 during the 17/18 flu-season,” *Eur. Respir. J.*, vol. 54, no. suppl 63, p. PA4566, Sep. 2019,
515 doi: [10.1183/13993003.congress-2019.PA4566](https://doi.org/10.1183/13993003.congress-2019.PA4566).

- 516 [9] S. D. Meskill, P. A. Revell, L. Chandramohan, and A. T. Cruz, “Prevalence of co-
517 infection between respiratory syncytial virus and influenza in children,” *Am. J. Emerg.*
518 *Med.*, vol. 35, no. 3, pp. 495–498, 2017, doi: <https://doi.org/10.1016/j.ajem.2016.12.001>.
- 519 [10] K. Bloom-Feshbach *et al.*, “Latitudinal variations in seasonal activity of influenza and
520 respiratory syncytial virus (RSV): a global comparative review.,” *PLoS One*, vol. 8, no. 2,
521 p. e54445, 2013, doi: [10.1371/journal.pone.0054445](https://doi.org/10.1371/journal.pone.0054445).
- 522 [11] A. Gordon and A. Reingold, “The Burden of Influenza: a Complex Problem.,” *Curr.*
523 *Epidemiol. reports*, vol. 5, no. 1, pp. 1–9, 2018, doi: [10.1007/s40471-018-0136-1](https://doi.org/10.1007/s40471-018-0136-1).
- 524 [12] M. Moghadami, “A Narrative Review of Influenza: A Seasonal and Pandemic Disease,”
525 *Iran. J. Med. Sci.*, vol. 42, no. 1, pp. 2–13, Jan. 2017, [Online]. Available:
526 <https://pubmed.ncbi.nlm.nih.gov/28293045>.
- 527 [13] R. K. Virk *et al.*, “Divergent evolutionary trajectories of influenza B viruses underlie their
528 contemporaneous epidemic activity,” *Proc. Natl. Acad. Sci.*, vol. 117, no. 1, pp. 619 LP –
529 628, Jan. 2020, doi: [10.1073/pnas.1916585116](https://doi.org/10.1073/pnas.1916585116).
- 530 [14] M. I. Nelson *et al.*, “Molecular Epidemiology of A/H3N2 and A/H1N1 Influenza Virus
531 during a Single Epidemic Season in the United States,” *PLOS Pathog.*, vol. 4, no. 8, p.
532 e1000133, Aug. 2008, [Online]. Available: <https://doi.org/10.1371/journal.ppat.1000133>.
- 533 [15] B. Lu *et al.*, “Emergence of new antigenic epitopes in the glycoproteins of human
534 respiratory syncytial virus collected from a US surveillance study, 2015–17,” *Sci. Rep.*,
535 vol. 9, no. 1, p. 3898, 2019, doi: [10.1038/s41598-019-40387-y](https://doi.org/10.1038/s41598-019-40387-y).
- 536 [16] J. C. Muñoz-Escalante, A. Comas-García, S. Bernal-Silva, C. D. Robles-Espinoza, G.
537 Gómez-Leal, and D. E. Noyola, “Respiratory syncytial virus A genotype classification
538 based on systematic intergenotypic and intragenotypic sequence analysis,” *Sci. Rep.*, vol.

- 539 9, no. 1, p. 20097, Dec. 2019, doi: 10.1038/s41598-019-56552-2.
- 540 [17] J. C. Muñoz-Escalante, A. Comas-García, S. Bernal-Silva, and D. E. Noyola, “Respiratory
541 syncytial virus B sequence analysis reveals a novel early genotype,” *Sci. Rep.*, vol. 11, no.
542 1, p. 3452, 2021, doi: 10.1038/s41598-021-83079-2.
- 543 [18] S. Ascough, S. Paterson, and C. Chiu, “Induction and subversion of human protective
544 immunity: Contrasting influenza and respiratory syncytial virus,” *Frontiers in*
545 *Immunology*, vol. 9, no. MAR. Frontiers Media S.A., p. 323, Mar. 02, 2018, doi:
546 10.3389/fimmu.2018.00323.
- 547 [19] G. González-Parra, F. De Ridder, D. Huntjens, D. Roymans, G. Ispas, and H. M.
548 Dobrovolny, “A comparison of RSV and influenza in vitro kinetic parameters reveals
549 differences in infecting time,” *PLoS One*, vol. 13, no. 2, p. e0192645, Feb. 2018, [Online].
550 Available: <https://doi.org/10.1371/journal.pone.0192645>.
- 551 [20] N. R. Waterlow, S. Flasche, A. Minter, and R. M. Eggo, “Competition between RSV and
552 influenza: Limits of modelling inference from surveillance data,” *Epidemics*, vol. 35, p.
553 100460, 2021, doi: <https://doi.org/10.1016/j.epidem.2021.100460>.
- 554 [21] G. Walzl, S. Tafuro, P. Moss, P. J. Openshaw, and T. Hussell, “Influenza virus lung
555 infection protects from respiratory syncytial virus-induced immunopathology,” *J. Exp.*
556 *Med.*, vol. 192, no. 9, pp. 1317–1326, Nov. 2000, doi: 10.1084/jem.192.9.1317.
- 557 [22] L. van Asten *et al.*, “Early occurrence of influenza A epidemics coincided with changes in
558 occurrence of other respiratory virus infections,” *Influenza Other Respi. Viruses*, vol. 10,
559 no. 1, pp. 14–26, Jan. 2016, doi: 10.1111/irv.12348.
- 560 [23] L. Opatowski, M. Baguelin, and R. M. Eggo, “Influenza interaction with cocirculating
561 pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key role

- 562 for mathematical modelling,” *PLOS Pathog.*, vol. 14, no. 2, p. e1006770, Feb. 2018,
563 [Online]. Available: <https://doi.org/10.1371/journal.ppat.1006770>.
- 564 [24] G. Walzl, S. Tafuro, P. Moss, P. J. Openshaw, and T. Hussell, “Influenza virus lung
565 infection protects from respiratory syncytial virus-induced immunopathology,” *J. Exp.*
566 *Med.*, vol. 192, no. 9, pp. 1317–1326, Nov. 2000, doi: 10.1084/jem.192.9.1317.
- 567 [25] S. M. Hartwig, A. M. Miller, and S. M. Varga, “Respiratory Syncytial Virus Provides
568 Protection against a Subsequent Influenza A Virus Infection,” *J. Immunol.*, vol. 208, no. 3,
569 pp. 720 LP – 731, Feb. 2022, doi: 10.4049/jimmunol.2000751.
- 570 [26] Y. Drori *et al.*, “Influenza A Virus Inhibits RSV Infection via a Two-Wave Expression of
571 IFIT Proteins,” *Viruses*, vol. 12, no. 10, Oct. 2020, doi: 10.3390/v12101171.
- 572 [27] B. Justin *et al.*, “Temporally structured metapopulation dynamics and persistence of
573 influenza A H3N2 virus in humans,” *Proc. Natl. Acad. Sci.*, vol. 108, no. 48, pp. 19359–
574 19364, Nov. 2011, doi: 10.1073/pnas.1109314108.
- 575 [28] L. Staaedegaard *et al.*, “Defining the seasonality of respiratory syncytial virus around the
576 world: National and subnational surveillance data from 12 countries,” *Influenza Other*
577 *Respi. Viruses*, vol. 15, no. 6, pp. 732–741, Nov. 2021, doi: 10.1111/irv.12885.
- 578 [29] E. Grilc, K. Prosenc Trilar, J. Lajovic, and M. Sočan, “Determining the seasonality of
579 respiratory syncytial virus in Slovenia,” *Influenza Other Respi. Viruses*, vol. 15, no. 1, pp.
580 56–63, Jan. 2021, doi: <https://doi.org/10.1111/irv.12779>.
- 581 [30] Y. Li, X. Wang, E. K. Broberg, H. Campbell, and H. Nair, “Seasonality of respiratory
582 syncytial virus and its association with meteorological factors in 13 European countries,
583 week 40 2010 to week 39 2019,” *Euro Surveill. Bull. Eur. sur les Mal. Transm. = Eur.*
584 *Commun. Dis. Bull.*, vol. 27, no. 16, Apr. 2022, doi: 10.2807/1560-

- 585 7917.ES.2022.27.16.2100619.
- 586 [31] M. Robertson *et al.*, “The spatial-temporal dynamics of respiratory syncytial virus
587 infections across the east–west coasts of Australia during 2016–17,” *Virus Evol.*, vol. 7,
588 no. 2, p. veab068, Dec. 2021, doi: 10.1093/ve/veab068.
- 589 [32] H. Chi, K.-L. Hsiao, L.-C. Weng, C.-P. Liu, and H.-F. Liu, “Persistence and continuous
590 evolution of the human respiratory syncytial virus in northern Taiwan for two decades,”
591 *Sci. Rep.*, vol. 9, no. 1, p. 4704, 2019, doi: 10.1038/s41598-019-41332-9.
- 592 [33] J. Schwarze, D. R. O’Donnell, A. Rohwedder, and P. J. M. Openshaw, “Latency and
593 Persistence of Respiratory Syncytial Virus Despite T Cell Immunity,” *Am. J. Respir. Crit.*
594 *Care Med.*, vol. 169, no. 7, pp. 801–805, Apr. 2004, doi: 10.1164/rccm.200308-1203OC.
- 595 [34] D. Zinder, T. Bedford, S. Gupta, and M. Pascual, “The Roles of Competition and
596 Mutation in Shaping Antigenic and Genetic Diversity in Influenza,” *PLOS Pathog.*, vol. 9,
597 no. 1, p. e1003104, Jan. 2013, [Online]. Available:
598 <https://doi.org/10.1371/journal.ppat.1003104>.
- 599 [35] T. Bedford, S. Cobey, and M. Pascual, “Strength and tempo of selection revealed in viral
600 gene genealogies,” *BMC Evol. Biol.*, vol. 11, p. 220, Jul. 2011, doi: 10.1186/1471-2148-
601 11-220.
- 602 [36] T. Bedford *et al.*, “Global circulation patterns of seasonal influenza viruses vary with
603 antigenic drift,” *Nature*, vol. 523, no. 7559, pp. 217–220, Jul. 2015, doi:
604 10.1038/nature14460.
- 605 [37] T. M. Paiva *et al.*, “Shift in the timing of respiratory syncytial virus circulation in a
606 subtropical megalopolis: implications for immunoprophylaxis,” *J. Med. Virol.*, vol. 84,
607 no. 11, pp. 1825–1830, Nov. 2012, doi: 10.1002/jmv.23347.

- 608 [38] L. Pinky and H. M. Dobrovolsky, “Coinfections of the Respiratory Tract: Viral
609 Competition for Resources,” *PLoS One*, vol. 11, no. 5, p. e0155589, May 2016, [Online].
610 Available: <https://doi.org/10.1371/journal.pone.0155589>.
- 611 [39] K. L. Laurie *et al.*, “Interval Between Infections and Viral Hierarchy Are Determinants of
612 Viral Interference Following Influenza Virus Infection in a Ferret Model,” *J. Infect. Dis.*,
613 vol. 212, no. 11, pp. 1701–1710, Dec. 2015, doi: 10.1093/infdis/jiv260.
- 614 [40] N. R. Waterlow *et al.*, “Evidence for influenza and RSV interaction from 10 years of
615 enhanced surveillance in Nha Trang, Vietnam, a modelling study,” *PLOS Comput. Biol.*,
616 vol. 18, no. 6, p. e1010234, Jun. 2022, [Online]. Available:
617 <https://doi.org/10.1371/journal.pcbi.1010234>.
- 618 [41] S. Ascough, S. Paterson, and C. Chiu, “Induction and Subversion of Human Protective
619 Immunity: Contrasting Influenza and Respiratory Syncytial Virus,” *Front. Immunol.*, vol.
620 9, p. 323, 2018, doi: 10.3389/fimmu.2018.00323.
- 621 [42] Y. Yang *et al.*, “Influenza A/H1N1 2009 Pandemic and Respiratory Virus Infections,
622 Beijing, 2009–2010,” *PLoS One*, vol. 7, no. 9, p. e45807, Sep. 2012, [Online]. Available:
623 <https://doi.org/10.1371/journal.pone.0045807>.
- 624 [43] P. Rohani, D. J. Earn, B. Finkenstädt, and B. T. Grenfell, “Population dynamic
625 interference among childhood diseases,” *Proc. R. Soc. London. Ser. B Biol. Sci.*, vol. 265,
626 no. 1410, pp. 2033–2041, Nov. 1998, doi: 10.1098/rspb.1998.0537.
- 627 [44] S. J. Olsen *et al.*, “Changes in Influenza and Other Respiratory Virus Activity During the
628 COVID-19 Pandemic - United States, 2020-2021,” *MMWR. Morb. Mortal. Wkly. Rep.*,
629 vol. 70, no. 29, pp. 1013–1019, Jul. 2021, doi: 10.15585/mmwr.mm7029a1.
- 630 [45] D. H. Charbonneau and L. N. James, “FluView and FluNet: Tools for Influenza Activity

- 631 and Surveillance,” *Med. Ref. Serv. Q.*, vol. 38, no. 4, pp. 358–368, Oct. 2019, doi:
632 10.1080/02763869.2019.1657734.
- 633 [46] “State Population Totals: 2010-2019.” [https://www.census.gov/data/tables/time-](https://www.census.gov/data/tables/time-series/demo/popest/2010s-state-total.html)
634 [series/demo/popest/2010s-state-total.html](https://www.census.gov/data/tables/time-series/demo/popest/2010s-state-total.html) (accessed Jul. 04, 2022).
- 635 [47] “Time Series Analysis and Its Applications: With R Examples - tsa4.”
636 <https://www.stat.pitt.edu/stoffer/tsa4/> (accessed Jul. 04, 2022).
- 637 [48] S. Kim, T. C. Williams, C. Viboud, H. Campbell, J. Chen, and D. J. Spiro, “RSV genomic
638 diversity and the development of a globally effective RSV intervention,” *Vaccine*, vol. 39,
639 no. 21, pp. 2811–2820, 2021, doi: <https://doi.org/10.1016/j.vaccine.2021.03.096>.
- 640 [49] S. F. Altschul, W. Gish, W. Miller, E. W. Myers, and D. J. Lipman, “Basic local
641 alignment search tool.,” *J. Mol. Biol.*, vol. 215, no. 3, pp. 403–410, Oct. 1990, doi:
642 10.1016/S0022-2836(05)80360-2.
- 643 [50] K. Katoh and D. M. Standley, “MAFFT multiple sequence alignment software version 7:
644 improvements in performance and usability,” *Mol. Biol. Evol.*, vol. 30, no. 4, pp. 772–780,
645 Apr. 2013, doi: 10.1093/molbev/mst010.
- 646 [51] A. Stamatakis, “RAxML version 8: a tool for phylogenetic analysis and post-analysis of
647 large phylogenies,” *Bioinformatics*, vol. 30, no. 9, pp. 1312–1313, May 2014, doi:
648 10.1093/bioinformatics/btu033.
- 649 [52] “Exploring the temporal structure of heterochronous sequences using TempEst (formerly
650 Path-O-Gen).” <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989882/> (accessed Aug.
651 07, 2020).
- 652 [53] B. Q. Minh, S. Klaere, and A. von Haeseler, “Taxon Selection under Split Diversity.,”
653 *Syst. Biol.*, vol. 58, no. 6, pp. 586–594, Dec. 2009, doi: 10.1093/sysbio/syp058.

- 654 [54] M. A. Suchard, P. Lemey, G. Baele, D. L. Ayres, A. J. Drummond, and A. Rambaut,
655 “Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10,” *Virus*
656 *Evol.*, vol. 4, no. 1, Jan. 2018, doi: 10.1093/ve/vey016.
- 657 [55] S. Tavaré and others, “Some probabilistic and statistical problems in the analysis of DNA
658 sequences,” *Lect. Math. life Sci.*, vol. 17, no. 2, pp. 57–86, 1986.
- 659 [56] B. Shapiro, A. Rambaut, and A. J. Drummond, “Choosing appropriate substitution models
660 for the phylogenetic analysis of protein-coding sequences,” *Mol. Biol. Evol.*, vol. 23, no.
661 1, pp. 7–9, Jan. 2006, doi: 10.1093/molbev/msj021.
- 662 [57] V. N. Minin, E. W. Bloomquist, and M. A. Suchard, “Smooth Skyride through a Rough
663 Skyline: Bayesian Coalescent-Based Inference of Population Dynamics,” *Mol. Biol. Evol.*,
664 vol. 25, no. 7, pp. 1459–1471, Jul. 2008, doi: 10.1093/molbev/msn090.
- 665 [58] A. Rambaut, A. J. Drummond, D. Xie, G. Baele, and M. A. Suchard, “Posterior
666 Summarization in Bayesian Phylogenetics Using Tracer 1.7,” *Syst. Biol.*, vol. 67, no. 5,
667 pp. 901–904, Sep. 2018, doi: 10.1093/sysbio/syy032.
- 668 [59] S. Shrestha, A. A. King, and P. Rohani, “Statistical Inference for Multi-Pathogen
669 Systems,” *PLOS Comput. Biol.*, vol. 7, no. 8, p. e1002135, Aug. 2011, [Online].
670 Available: <https://doi.org/10.1371/journal.pcbi.1002135>.
- 671 [60] C. Y. Lin, “Modeling Infectious Diseases in Humans and Animals by KEELING, M. J.
672 and ROHANI, P.,” *Biometrics*, vol. 64, no. 3, p. 993, Sep. 2008, doi:
673 https://doi.org/10.1111/j.1541-0420.2008.01082_7.x.
- 674 [61] A. A. King, D. Nguyen, and E. L. Ionides, “Statistical Inference for Partially Observed
675 Markov Processes via the R Package pomp,” *J. Stat. Softw.*, vol. 69, no. 12 SE-Articles,
676 pp. 1–43, Mar. 2016, doi: 10.18637/jss.v069.i12.

677 [62] S. J. Olsen *et al.*, “Changes in Influenza and Other Respiratory Virus Activity During the
678 COVID-19 Pandemic - United States, 2020-2021,” *MMWR. Morb. Mortal. Wkly. Rep.*,
679 vol. 70, no. 29, pp. 1013–1019, Jul. 2021, doi: 10.15585/mmwr.mm7029a1.
680